Healthcare utilization and costs among chronic bronchitis patients treated with maintenance medications from a US managed care population

Journal of Medical Economics

Volumn 16, Issue 3, 2013, Pages 421-429

  Abudagga, Azza ^a   Sun, Shawn X ^b   Tan, Hiangkiat ^a   Solem, Caitlyn T ^c  

^a HEALTHCORE INC   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c PHARMERIT INTERNATIONAL   (United States)

Author keywords

Chronic bronchitis; COPD maintenance medications; Healthcare utilization and costs

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; EMERGENCY PATIENT; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; RETROSPECTIVE STUDY; UNITED STATES;

ADULT; AGED; BRONCHITIS, CHRONIC; FEMALE; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; MAINTENANCE CHEMOTHERAPY; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84873919062     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.766614     Document Type: Article

References (21)

1. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD Executive Summary. Am J Respir Crit Care Med 2012Aug 9. [Epub ahead of print]
2. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000;117:5S-9S
3. Minino SL, Xu JQ, Kochanek KD. Deaths: preliminary data for 2008. National Vital Statistics Reports 2010;59:1-52
4. Murphy SL, Xu JQ, Kochanek KD. Deaths: preliminary data for 2010. National Vital Statistics Reports 2012;60:1-69
5. National Heart, Lung, and Blood Institute (NHLBI). Morbidity and mortality: 2009 chart book on cardiovascular, lung, and blood diseases. Bethesda, MD: National Heart, Lung, and Blood Institute, 2009. http://www.nhlbi.nih.gov/resources/docs/2009-ChartBook.pdf Accessed October 23, 2012
6. Dalal AA, Shah M, Lunacsek O, et al. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. Respir Med 2011;105:1516-22
7. Blanchette CM, Dalal AA, Mapel D. Changes in COPD demographics and costs over 20 years. J Med Econ 2012;15:1176-82 [Epub 1 August 2012]
8. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117:398S-401S
9. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003;41:46s-53s
10. Gagnon YM, Levy AR, Spencer MD, et al. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting (62-agonists in a health maintenance organization. Respir Med 2005;99:1534-45
11. Blanchette CM, Roberts MH, Petersen H, et al. Economic burden of chronic bronchitis in the United States: a retrospective case-control study. Int J Chron Obstruct Pulmon Dis 2011;6:73-81
12. Donaldson GC, Wedzicha JA. COPD exacerbations. 1: epidemiology. Thorax 2006;61:164-8
13. Blais L, Forget A, Ramachandran S. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clin Ther 2010;32:1320-8
14. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9
15. Mapel DW, Dutro MP, Marton JP, et al. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data. BMC Health Serv Res 2011;11:43
16. Bureau of Labor Statistics, US Department of Labor. Measuring price change for medical care in the CPI. Last updated April 12, 2010. http://www.bls.gov/cpi/cpifact4.htm. Accessed October 1, 2011
17. Akazawa M, Halpern R, Riedel AA, et al. Economic burden prior to COPD diagnosis: a matched case-control study in the United States. Respir Med 2008;102:1744-52
18. Mapel DW, Schum M, Lydick E, et al. A new method for examining the cost savings of reducing COPD exacerbations. Pharmacoeconomics 2010;28:733-49
19. Yu AP, Yang H, Wu EQ, et al. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ 2011;14:315-23
20. Mapel DW, McMillan GP, Frost FJ, et al. Predicting the costs of managing patients with chronic obstructive pulmonary disease. Respir Med 2005;99:1325-33
21. Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD-a review of potential interventions. Int J Chron Obstruct Pulmon Dis 2009;4:203-23